Bococizumab 是一种抗人 PCSK9 抑制抗体，可降低 LDL 胆固醇水平 | MedChemExpress (MCE)

Bococizumab

CAS：1407495-02-6

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Bococizumab (PF-04950615) 是一种抗人 PCSK9 抑制抗体，可降低 LDL 胆固醇水平。 Bococizumab可用于高胆固醇血症的研究[1][2]。 IC50 和目标：PCSK9。

体内：Bococizumab（0-100 mg/kg，静脉注射）降低母体和胎儿的胆固醇并且不影响大鼠胚胎-胎儿发育[2]。

详情：www.medchemexpress.cn/bococizumab.html

参考文献：

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505.
[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.